...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Equity financing
9
Jun 06, 2018 06:09PM

If for ZCC, then this means that subscribers to this ZCC offering will have a stake in the Resverlogix Royalty Preferred Shares. More dilution of the RPSs. Boo.

2
Jun 07, 2018 04:40PM
7
Jun 07, 2018 05:03PM
2
Jun 07, 2018 05:54PM
5
Jun 25, 2018 01:59PM
3
Jun 25, 2018 03:27PM
5
Jun 25, 2018 09:01PM
Share
New Message
Please login to post a reply